|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The median CD8 tumor-infiltrating lymphocyte density was significantly higher in vulvar/vaginal than cervical melanomas and correlated with PD-L1 expression.
|
31383965 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma is a deadly tumor which in recent years has been successfully treated with immune checkpoint inhibitors as PD-1/PD-L1 and CTLA-4 inhibitors and targeted therapy as BRAF and MEK inhibitors.
|
31785018 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, classical Hodgkin lymphoma, colorectal cancer, gastroesophageal cancer, hepatocellular cancer, and other solid tumors.
|
31584451 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our in vitro data demonstrate PD-L1 induction on melanoma cells in the blood.This study established a robust, reliable method to isolate melanoma CTCs and detect expression of PD-L1 on these cells.
|
30735560 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
|
31741766 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: These findings identify PD-L1 as a critical component of UV-induced immune suppression in the skin, which facilitates immunoevasion of oncogenic melanocytes and development of melanoma.<i>See related commentary by Sahu, p. 2805</i>.
|
30737234 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SPECT/CT imaging in mice following intravenous injection of Technetium-99m (<sup>99m</sup>Tc)-labeled sdAb K2 revealed high signal-to-noise ratios, strong ability to specifically detect PD-L1 in melanoma and breast tumors, and relatively low kidney retention, which is a unique property for radiolabeled sdAbs.
|
31234464 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
|
31335487 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analyses of 97 melanoma tissue samples showed significant correlations between CD74 and the expression status of PD-L1 (P < .01).
|
31069878 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, therapeutic vaccination with mRNA Galsomes enhanced the responsiveness to treatment with a PD-L1 checkpoint inhibitor in B16-OVA melanoma, as evidenced by a synergistic reduction of tumor outgrowth and a significantly prolonged median survival.
|
30742405 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-PD-1 or anti-PD-L1 therapy has induced tumor regression and improved clinical outcome in patients with different tumor entities, including melanoma, non-small-cell lung cancer, and renal cell carcinoma.
|
31557787 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While inhibitors to CTLA-4 and the PD-1/PD-L1 axis are well-established for the clinical management of melanoma, many patients do not respond or develop resistance to these interventions.
|
30941125 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 positivity was observed in 33% and 39% of primary melanomas and matched metastases, respectively, with, however, poor concordance between the primary and the matched metastatic site (κ = 0.283).
|
31625630 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal the potential of CTCs as a noninvasive real-time biopsy to evaluate PD-L1 expression in patients with melanoma.
|
31806779 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such as melanoma and lung cancer.
|
31031765 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-1/PD-L1 blockade in NSCLC and UC increase the risk of immune-related liver dysfunction, but not in melanoma (MM) and head-neck squamous cell carcinoma (HNSCC).
|
31607917 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as small molecule inhibitors of BRAF and/or MEK for the subgroup of patients with BRAF<sup>V600</sup> mutations<sup>1-9</sup>.
|
31171876 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
|
30487198 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on the recent development of biomarkers for assessing the efficacy of anti-PD1 antibodies using routine blood tests such as the neutrophil-to-lymphocyte ratio, eosinophil ratio, serum markers such as lactate dehydrogenase, programmed cell death ligand 1 (PD-L1) expression on melanoma cells, microsatellite instability and mismatch repair deficiency assays, as well as soluble CD163, and tumor-associated macrophage-related chemokines (e.g., CXCL5, CXCL10).
|
31417907 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) checkpoint blockade which has improved survival.
|
31128215 |
2019 |
|
melanoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Based on our findings, measuring and altering PD-L1 promoter DNA methylation may have potential prognostic and therapeutic applications in melanoma.
|
30343532 |
2019 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAF<sup>V600</sup> mutant status or consented to BRAF<sup>V600</sup> mutation testing during screening.
|
31221619 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that NBDs may represent a promising treatment strategy for melanoma with elevated PD-L1 expression.
|
31639786 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The observed immunological differences suggest a conceivable role of increased intratumoural macrophage and dendritic cell counts associated with enhanced tumour cell PD-L1 expression potentially contributing to the immunosuppressive, growth-promoting microenvironment of ulcerated primary melanomas.
|
30357969 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, CDK4/6 inhibitor (palbociclib) treatment increased PD-L1 protein levels and enhanced efficacy (<i>P</i> < 0.05) in the C57BL/6-hPD-1 melanoma cell and the HIS PDX model.
|
31375512 |
2019 |